Compound Mechanism of action Target indication Status More Information

QUVIVIQ™   (daridorexant)

Dual orexin receptor antagonist


Commercially available in the US, Germany, Italy, Switzerland, Spain, UK, Canada, and Austria;
Approved throughout the EU;
Phase 2 in pediatric insomnia – recruiting

Investor webcast


Dual endothelin receptor antagonist

Resistant hypertension

NDA under review in the US, MAA under review in the EU, other filings in preparation

Investor webcast


Glucosylceramide synthase inhibitor

Fabry disease

Phase 3 primary endpoint not met, open-label extension study ongoing



P2Y12 inhibitor

Suspected acute myocardial infarction

Phase 3 recruiting



S1P1 receptor modulator

Systemic lupus erythematosus

Phase 3 recruiting



ACKR3 / CXCR7 antagonist

Multiple sclerosis and other demyelinating diseases

Phase 2 in preparation



GBA2/GCS inhibitor

Rare lysosomal storage disorders

Phase 1 complete



C5aR1 antagonist

Immune-mediated disorders

Phase 1



CXCR3 antagonist

Recent-onset Type 1 diabetes

Phase 1




Immune-mediated disorders

Phase 1


Synthetic glycan vaccine

Clostridium difficile infection

Phase 1 in preparation


*On February 28, 2024, Idorsia announced that it has entered into an agreement with Viatris for the global development and commercialization of selatogrel and cenerimod. The company expects to close the transaction by the end of March, subject to customary closing conditions, but no additional regulatory or shareholder approvals are required.

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker.

On July 20, 2023, Idorsia sold its operating businesses in the Asia Pacific (ex-China) region to Sosei Heptares, including the assignment of the license for PIVLAZ (clazosentan) for the Asia Pacific (ex-China) region. Idorsia retains the rights to clazosentan in the rest of the world.